中国P站

Population Pharmacokinetics; Drug Development; Personalized Medicine; Physiologically Based Pharmacokinetic Modeling; Bayesian Analysis; Pharmacogenomics; Real-World Data; Drug-Drug Interactions; Machine Learning; Model-Informed Drug Development

Introduction

Population pharmacokinetic (PopPK) modeling stands as an indispensable methodology within the landscape of drug development and clinical practice. Its capacity to elucidate how variations in patient characteristics, encompassing age, weight, organ function, and genetic makeup, alongside disease states, influence drug exposure and therapeutic outcomes is paramount. This approach is fundamental for refining dosing strategies, identifying patient subgroups that might necessitate distinct treatment regimens, and providing crucial data for regulatory assessments. The evolution of PopPK modeling is increasingly marked by the integration of diverse data sources, including omics data and real-world evidence, coupled with sophisticated statistical techniques to construct more predictive and insightful models, aiming for personalized medicine. [1] In parallel, the fusion of physiologically based pharmacokinetic (PBPK) modeling with traditional PopPK methodologies is gaining significant traction and prominence. PBPK models achieve this by incorporating detailed biological and physicochemical properties of both drugs and human organs, thereby offering mechanistic explanations for the pharmacokinetic variability identified in PopPK studies. This synergistic integration substantially elevates the predictive capabilities of these models, proving particularly beneficial for anticipating drug-drug interactions, understanding drug behavior in special populations such as pediatric or geriatric patients, and individuals with compromised renal or hepatic function, and for making accurate first-in-human dose predictions. [2] Bayesian PopPK analysis presents a distinct set of advantages, especially when confronted with sparse data scenarios, which are frequently encountered in the early phases of drug development or within specific patient cohorts. This analytical framework permits the incorporation of existing knowledge, derived from prior investigations or studies on analogous drugs, directly into the analysis. The consequence of this integration is the derivation of more robust and precise parameter estimates, enhancing the reliability of the model. Furthermore, the adoption of Bayesian approaches significantly facilitates the implementation of adaptive dosing strategies, allowing for dynamic adjustments based on accumulating patient data. [3] The profound influence of genetic polymorphisms on drug disposition represents a critical area of investigation within PopPK research. A comprehensive understanding of how variations in genes encoding key elements such as drug-metabolizing enzymes, transporters, or drug targets can alter pharmacokinetic profiles and subsequently impact clinical results is essential for the successful implementation of pharmacogenomic-guided therapy. PopPK models serve as a powerful tool for quantifying the specific impact of these genetic factors and for developing meticulously tailored dosing recommendations that account for individual genetic variations. [4] Real-world data (RWD), encompassing sources like electronic health records and insurance claims databases, is progressively being harnessed for PopPK studies. This innovative approach enables the assessment of drug performance across a broader spectrum of more heterogeneous patient populations as they are encountered in routine clinical practice. The strategic utilization of RWD in PopPK modeling has the potential to yield more generalizable findings, offering valuable insights that can inform post-market surveillance activities and drug utilization studies, thereby extending the understanding of drug behavior beyond controlled trial settings. [5] The intricate process of developing pediatric dosing regimens poses considerable challenges, and PopPK modeling emerges as a critical tool in navigating these complexities. Factors inherent to children, such as rapid physical growth, ongoing organ maturation, and distinct physiological differences compared to adults, necessitate highly specialized pharmacokinetic approaches. PopPK models, often used in conjunction with PBPK models, are instrumental in bridging the pharmacokinetic knowledge gap between adult and pediatric populations, thereby ensuring the safe and effective administration of drugs to this particularly vulnerable demographic. [6] Drug-drug interactions (DDIs) constitute a significant concern in contemporary clinical practice, frequently impacting both the efficacy and safety profiles of medications. PopPK models play an instrumental role in characterizing the extent and variability associated with these DDIs. By enabling the identification of patient subgroups that are particularly susceptible to interactions or by facilitating the prediction of interaction risks based on concomitant medications and individual patient factors, PopPK analysis can provide essential guidance for prescribing decisions and inform the content of drug labeling, thereby mitigating potential adverse events. [7] The application of sparse sampling strategies, frequently dictated by practical considerations and the convenience of patients, is a common characteristic of many PopPK studies. To maximize the informational yield from such limited data collections, sophisticated statistical methodologies are employed. These advanced techniques, which include adaptive sampling designs and Bayesian inference methods, are crucial for extracting robust parameter estimates and ensuring the reliability of model predictions, even when faced with data constraints. [8] The integration of machine learning (ML) and artificial intelligence (AI) into the realm of PopPK represents a burgeoning and exciting frontier. ML algorithms possess a remarkable capacity for identifying intricate patterns and complex non-linear relationships within large datasets that might otherwise remain undetected by traditional analytical methods. This enhanced analytical power can lead to significant improvements in the prediction of drug response and the identification of novel covariates that exert an influence on pharmacokinetic processes. [9] Model-informed drug discovery and development (MIDD) is a paradigm that relies heavily on the principles and applications of PopPK. This approach guides the critical process of dose selection, extending from preclinical investigations through to late-stage clinical trials, and provides essential quantitative support for regulatory submissions. PopPK models offer a robust quantitative framework for comprehending pharmacokinetic variability, predicting therapeutic efficacy and potential toxicity, and optimizing dosing regimens, ultimately contributing to the development of safer and more effective pharmaceutical agents. [10]

Description

Population pharmacokinetic (PopPK) modeling serves as a cornerstone in the sophisticated process of drug development and its subsequent clinical application. It empowers researchers and clinicians to meticulously understand how intrinsic patient variability, manifested in age, weight, organ function, and genetic makeup, as well as extrinsic factors like disease states, collectively shape drug exposure and ultimately, patient response. This comprehensive understanding is absolutely vital for optimizing dosing strategies, accurately identifying subpopulations that may require tailored therapeutic regimens, and providing evidence-based information to inform regulatory decision-making. The ongoing advancements in this field are characterized by the progressive integration of diverse data streams, such as omics data and real-world evidence, alongside cutting-edge statistical techniques, all aimed at constructing more predictive and informative PopPK models that can pave the way for personalized medicine. [1] The burgeoning synergy between physiologically based pharmacokinetic (PBPK) modeling and established PopPK approaches marks a significant evolution in the field. PBPK models achieve a deeper mechanistic understanding by meticulously incorporating the biological and physicochemical attributes of both drugs and human organs. This detailed representation allows them to elucidate the underlying biological reasons for pharmacokinetic variability that is observed in PopPK studies. The combined power of these integrated modeling approaches markedly enhances predictive accuracy, proving especially valuable for anticipating the complex outcomes of drug-drug interactions, for characterizing drug behavior in specialized patient groups such as pediatric and geriatric populations, and in individuals suffering from renal or hepatic impairment, and for forecasting safe and effective first-in-human doses. [2] Bayesian PopPK analysis offers substantial benefits, particularly in situations where data is limited or sparse, a common scenario encountered during the early stages of drug development or when studying specific patient cohorts. This analytical methodology facilitates the incorporation of prior knowledge, derived from previous studies or information on similar drugs, directly into the current analysis. Consequently, this leads to more stable and precise estimates of pharmacokinetic parameters, thereby increasing the reliability of the model. Furthermore, the application of Bayesian techniques streamlines the development and implementation of adaptive dosing strategies, which can be adjusted dynamically based on incoming patient data. [3] A critical area of focus within PopPK is the investigation of how genetic polymorphisms influence drug disposition. Elucidating the impact of variations in genes responsible for encoding drug-metabolizing enzymes, transporters, or drug targets is fundamental to understanding how pharmacokinetic profiles are altered and how subsequent clinical outcomes are affected. This knowledge is indispensable for the successful implementation of pharmacogenomic-guided therapy. PopPK models provide a quantitative framework to precisely measure the effect of these genetic factors, enabling the development of highly individualized dosing recommendations. [4] The utilization of real-world data (RWD), which includes sources such as electronic health records and insurance claims data, is becoming increasingly prevalent in PopPK studies. This innovative approach permits the evaluation of drug performance within broader and more diverse patient populations, reflecting the conditions of routine clinical practice. The strategic leveraging of RWD in PopPK modeling can lead to findings that possess greater generalizability, thereby providing valuable insights that can inform post-market surveillance initiatives and drug utilization research. [5] The development of appropriate dosing regimens for pediatric populations presents a significant and complex challenge, with PopPK modeling playing an absolutely critical role in addressing it. The unique physiological characteristics of children, including rapid growth, ongoing organ maturation, and distinct physiological processes compared to adults, necessitate specialized pharmacokinetic approaches. PopPK models, often utilized in conjunction with PBPK models, are essential tools for bridging the pharmacokinetic differences observed between adults and children, thereby ensuring that medications are used safely and effectively in this especially vulnerable patient group. [6] Drug-drug interactions (DDIs) represent a major public health concern in clinical settings, frequently compromising drug efficacy and jeopardizing patient safety. PopPK models are instrumental in comprehensively characterizing the magnitude and the inherent variability associated with DDIs. By enabling the identification of patient populations that are particularly susceptible to such interactions or by predicting potential interaction risks based on concomitant medications and individual patient characteristics, PopPK analysis provides crucial guidance for prescribing decisions and informs the labeling of medications to enhance safety. [7] The implementation of sparse sampling strategies, often necessitated by practical constraints and patient convenience, is a common feature of PopPK studies. To extract the maximum possible information from these limited datasets, advanced statistical methodologies are indispensable. These sophisticated techniques, which encompass adaptive sampling designs and Bayesian inference methods, are crucial for obtaining robust parameter estimates and ensuring the predictive reliability of the developed models, even when faced with data scarcity. [8] The integration of machine learning (ML) and artificial intelligence (AI) into the discipline of PopPK represents an exciting and rapidly advancing frontier. ML algorithms demonstrate a remarkable ability to identify complex patterns and non-linear relationships within extensive datasets that traditional methods might overlook. This capability can significantly enhance the prediction of drug responses and facilitate the identification of novel covariates that influence pharmacokinetic processes, leading to more precise and individualized therapeutic strategies. [9] Model-informed drug discovery and development (MIDD) is a strategic framework that fundamentally relies on the principles and applications of PopPK. This integrated approach is crucial for guiding the critical process of dose selection, spanning from initial preclinical studies through to the advanced stages of clinical trials, and provides essential quantitative support for the regulatory submission process. PopPK models offer a robust quantitative framework that enables a thorough understanding of pharmacokinetic variability, facilitates the prediction of both therapeutic efficacy and potential toxicity, and supports the optimization of dosing regimens, ultimately contributing to the development of safer and more effective medicines. [10]

Conclusion

Population pharmacokinetic (PopPK) modeling is a crucial tool in drug development and clinical practice, enabling the understanding of how patient variability influences drug exposure and response. It is vital for optimizing dosing, identifying specific patient needs, and informing regulatory decisions. Advancements include integrating omics data and real-world evidence. The combination of PopPK with physiologically based pharmacokinetic (PBPK) modeling enhances predictive power, especially for drug-drug interactions and special populations. Bayesian PopPK analysis is advantageous for sparse data, offering stable parameter estimates and supporting adaptive dosing. Genetic polymorphisms influencing drug disposition are key areas explored by PopPK for pharmacogenomic-guided therapy. Real-world data enhances the generalizability of PopPK findings. PopPK is critical for developing safe and effective pediatric dosing regimens and for characterizing and managing drug-drug interactions. Sparse sampling strategies are addressed with advanced statistical methods. Machine learning and AI integration are emerging, promising improved prediction and covariate identification. Ultimately, PopPK underpins model-informed drug discovery and development (MIDD), guiding dose selection and regulatory submissions for safer, more effective medicines.

References

1. David MA, Katarzyna MG, Pawe艂 MK. (2021) .Clin Pharmacol Ther 110:709-712.

   , ,

2. Jingjing W, Min Z, David BR. (2023) .Clin Pharmacokinet 62:885-902.

   , ,

3. Xiaohui L, Baojian X, Guangrong C. (2022) .J Clin Pharmacol 62:1438-1449.

   , ,

4. Yoshihiro S, Hiroyuki I, Kazuko M. (2021) .Br J Clin Pharmacol 87:4353-4370.

   , ,

5. Amir HZ, Reza BA, Mahyar F. (2023) .Pharmacoepidemiol Drug Saf 32:1015-1026.

   , ,

6. Junli W, Ying Z, Chunqing D. (2022) .Pediatr Drugs 24:643-656.

   , ,

7. Yujie W, Daqing L, Xuan M. (2023) .Expert Opin Drug Metab Toxicol 19:243-258.

   , ,

8. Ferdinand VN, Jan GVH, Janine TJvL. (2021) .CPT Pharmacometrics Syst Pharmacol 10:1097-1106.

   , ,

9. Pengfei Z, Ting L, Yuan W. (2023) .Pharmaceutics 15:20.

   , ,

10. Xiaomeng G, Ying D, Shuting L. (2022) .Clin Transl Sci 15:1151-1157.

    , ,